REG - Immupharma PLC - Appointment of Company Secretary

ImmuPharmaAnnouncement

18/01/2021 07:00

RNS Number : 9000L
  
Immupharma PLC
  
18 January 2021
  
 

 
 
 
18 January 2021
ImmuPharma PLC
("ImmuPharma" or the "Company")
 
Appointment of Company Secretary
 
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is pleased to announce that Ewa Flynn, the Company's Financial Controller, was appointed as Company Secretary on 15 January 2021.
 



For further information please contact:
 



ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chairman


+ 44 (0) 207 152 4080




Dimitri Dimitriou, Chief Executive Officer








Lisa Baderoon, Head of Investor Relations


+ 44 (0) 7721 413496
 
 




SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
 
Stanford Capital Partners (Joint Broker) 
Patrick Claridge
John Howes
Bob Pountney 
 
SI Capital (Joint Broker)
Nick Emerson
 


+44 (0) 203 368 3550
 
 
+44 (0) 203 815 8880
 
 
+44 (0) 1483 413500
 
 




4Reliance (Euronext Growth Listing Sponsor)
Jean-Charles Snoy
 
Degroof Petercam (Liquidity Provider)
Erik De Clippel
 
Backstage Communication
Olivier Duquaine
Gunther De Backer


+32 (0) 2 747 02 60
 
 
+32 (0) 2 287 95 34
 
 
 
+32 (0) 477 504 784
+32 (0) 475 903 909
 

















 
 
Notes to Editors 
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US. 
 
For additional information about ImmuPharma please visit www.immupharma.co.uk 
 
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
COSBXGDBXXBDGBU